Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 179Genitourinary 11Thoracic 10Gynecologic 10Breast 8Sarcoma 7Head & Neck 7Endocrine 4Dermatologic 3CNS 3Other solid neoplasm 2NET 2Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 985Leukemia 733Leukemia, Lymphocytic, Chronic, B-Cell 665Precursor Cell Lymphoblastic Leukemia-Lymphoma 605Myelodysplastic Syndromes 502Lymphoma 340Leukemia, Myelogenous, Chronic, BCR-ABL Positive 308Lymphoma, Non-Hodgkin 294Hematologic Neoplasms 257Lymphoma, Follicular 223Multiple Myeloma 213Burkitt Lymphoma 209Hodgkin Disease 198Lymphoma, Large B-Cell, Diffuse 194Lymphoma, Mantle-Cell 193Lymphoma, B-Cell, Marginal Zone 189Leukemia, Myelomonocytic, Chronic 181Leukemia, Myeloid, Chronic-Phase 171Recurrence 167Myeloproliferative Disorders 165Congenital Abnormalities 140Lymphoma, Large-Cell, Immunoblastic 132Leukemia, Myeloid, Accelerated Phase 118Blast Crisis 115Anemia, Refractory, with Excess of Blasts 114Waldenstrom Macroglobulinemia 103Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 102Primary Myelofibrosis 94Graft vs Host Disease 88Neoplasms, Plasma Cell 84

Interventions

trametinib 1dabrafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Biliary Tract Neoplasms × Other hematologic neoplasm × Clear all
NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Novartis

Phase 2 Completed
206 enrolled 40 charts 2 FDA
CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡